Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.18M | 12.74M | 8.13M | 7.70M | 7.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.95M | 60.24M | 41.12M | 40.68M | 32.02M |
| Operating Income | -59.95M | -60.24M | -41.12M | -40.68M | -32.02M |
| Income Before Tax | -55.38M | -56.16M | -37.33M | -36.29M | -27.34M |
| Income Tax Expenses | 61.00K | 52.00K | 53.00K | 40.00K | 52.00K |
| Earnings from Continuing Operations | -55.44M | -56.21M | -37.39M | -36.33M | -27.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.44M | -56.21M | -37.39M | -36.33M | -27.39M |
| EBIT | -59.95M | -60.24M | -41.12M | -40.68M | -32.02M |
| EBITDA | -59.91M | -60.20M | -41.08M | -40.65M | -32.00M |
| EPS Basic | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 |
| Normalized Basic EPS | -0.51 | -0.58 | -0.42 | -0.42 | -0.31 |
| EPS Diluted | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 |
| Normalized Diluted EPS | -0.51 | -0.58 | -0.42 | -0.42 | -0.31 |
| Average Basic Shares Outstanding | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M |
| Average Diluted Shares Outstanding | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |